...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Inhibition of hepatic apolipoprotein A-I gene expression by histamine
【24h】

Inhibition of hepatic apolipoprotein A-I gene expression by histamine

机译:组胺的抑制肝脂蛋白A-I基因表达

获取原文
获取原文并翻译 | 示例
           

摘要

In a recent high throughput analysis to identify drugs that alter hepatic apolipoprotein A-I (apo A-I) expression, histamine receptor one (H-1) antagonists emerged as potential apo A-1 inducing drugs. Thus the present study was undertaken to identify some of the underlying molecular mechanisms of the effect of antihistaminic drugs on apo AI production. Apo A-I levels were measured by enzyme immunoassay and Western blots. Apo A-I mRNA levels were measured by reverse transcription real-time PCR using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA as the internal control. The effects of histamine and antihistamines on apo A-I gene were determined by transient transfection of plasmids containing the apo A-I gene promoter. Histamine repressed while (H-1) receptor antagonist azelastine increased apo A-I protein and mRNA levels within 48 h in a dose-dependent manner. Azelastine and histamine increased and suppressed, respectively, apo A-I gene promoter activity through a peroxisome proliferator activated receptor a response element. Treatment of HepG2 cells with other H-1 receptor antagonists including fexofenadine, cetirizine, and diphenhydramine increased apo A-I levels in a dose-dependent manner while treatment with H-2 receptor antagonists including cimetidine, famotidine, and ranitidine had no effect. We conclude that H-1 receptor signaling is a novel pathway of apo A1 gene expression and therefore could be an important therapeutic target for enhancing de-novo apo A-1 synthesis.
机译:在近期高通量分析中鉴定改变肝脂蛋白A-I(APO A-I)表达的药物,组胺受体一种(H-1)拮抗剂作为潜在的APO A-1诱导药物。因此,本研究鉴定了抗组胺药药物对AIA生产作用影响的一些潜在的分子机制。 APO A-I水平通过酶免疫测定和Western印迹测量。通过使用甘油醛-3-磷酸脱氢酶(GAPDH)mRNA作为内部对照,通过逆转录实时PCR测量APO A-I mRNA水平。通过含有APO A-I基因启动子的质粒的瞬时转染确定组胺和抗组胺的影响APO A-I基因。组胺抑制的同时(H-1)受体拮抗剂偶氮物增加了48小时内的APO A-1蛋白和mRNA水平,以剂量依赖性方式。偶氮物和组胺分别增加和抑制APO A-I基因启动子活性通过过氧化物体增殖剂活化受体响应元件。用其他H-1受体拮抗剂治疗HepG2细胞,包括FexofeNAdine,Cetirizine和二合一萘胺以剂量依赖性方式增加APO A-1水平,同时用包括西咪替丁,法替啶和Ranitidine的H-2受体拮抗剂的治疗无效。我们得出结论,H-1受体信号传导是APO A1基因表达的新途径,因此可以是增强De-Novo APO A-1合成的重要治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号